ImmunityBio’s Legal and Financial Trajectories Diverge Sharply

ImmunityBio finds itself navigating a stark dichotomy. While its commercial engine, driven by the cancer drug ANKTIVA, is firing on all cylinders, the company faces mounting legal and regulatory challenges that have spooked investors and triggered a wave of shareholder lawsuits. This tension defines the current investment thesis for the biotech firm.

The immediate catalyst for the legal turmoil was a consumer podcast titled “Is the FDA BLOCKING Life Saving Cancer Treatments?” which aired on January 19, 2026, and featured Executive Chairman Patrick Soon-Shiong. Plaintiffs in a subsequent class action allege the program significantly overstated ANKTIVA’s capabilities, including calling it a cancer vaccine. The U.S. Food and Drug Administration responded with a warning letter dated March 13, made public on March 24, which cited the podcast and a TV advertisement for misbranding the drug. This was not the first regulatory note; the agency had sent similar communications to an ImmunityBio subsidiary in September 2025 and January 2026.

The market’s reaction was severe. On March 24, the stock plummeted approximately 21% in a single session, falling from $9.40 to $7.41 and wiping nearly $2 billion from the company’s market capitalization. This sell-off forms the core of the consolidated class action lawsuit Douglas v. ImmunityBio, which covers the period from January 19 to March 24, 2026. The legal filing also incorporates an earlier 12% drop on January 23, when the stock fell to $6.45 following the release of interim Phase 2 data for a glioblastoma study where the primary endpoint had not yet been met.

Major law firms, including Schall Law, Faruqi & Faruqi, Hagens Berman, and Kessler Topaz, have since mobilized, contacting investors and filing suits. The deadline for lead plaintiff motions is set for May 26, 2026. In response to the FDA, ImmunityBio filed a detailed statement on April 6, removed the podcast from its website, confirmed the cited TV ad never aired, and pledged stricter internal review processes.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Despite this backdrop, the company’s financial performance tells a different story. Preliminary net product revenue for the first quarter of 2026 surged 168% year-over-year to approximately $44.2 million. The company ended the quarter with a solid liquidity position of about $381 million. It also bolstered its balance sheet through a $75 million non-dilutive capital draw from Oberland Capital, bringing the total under that agreement to $375 million, and converted $25 million of debt into equity.

This robust commercial execution underpins significant analyst optimism, creating a wide gap between the current share price of around $8.20 and Wall Street’s targets. D. Boral Capital maintains a $23 price target, implying upside potential of nearly 181%, alongside a Buy rating. BTIG and Piper Sandler are more conservative with targets of $13 and $12, respectively, but still see the stock as a buy. The average analyst price target sits at $14.40.

The long-term growth narrative is anchored by ANKTIVA’s global rollout. ImmunityBio recently confirmed the drug’s commercial availability in Saudi Arabia for bladder and lung cancers through partnerships. ANKTIVA is now approved across five jurisdictions covering 34 countries, including a conditional marketing authorization from the European Commission. Management projects annual revenue of $1.2 billion and profit of about $435 million by 2029, while some independent analysts see potential for $1.6 billion in revenue and nearly $672 million in profit.

For now, with a market cap hovering near $7.5 billion, ImmunityBio remains a loss-making company as it spends to fuel expansion; analysts expect a loss per share of $0.31 for the current fiscal year. The coming weeks will test whether its record commercial momentum can ultimately outweigh the substantial legal overhang, with the May 26 court deadline serving as the next major milestone.